These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

13309 related items for PubMed ID: 11690551

  • 21. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
    Guinness ME, Kenney JL, Reiss M, Lacy J.
    Cancer Res; 2000 Oct 01; 60(19):5354-8. PubMed ID: 11034070
    [Abstract] [Full Text] [Related]

  • 22. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function.
    Liu XF, Xia YF, Li MZ, Wang HM, He YX, Zheng ML, Yang HL, Huang WL.
    Cell Biol Int; 2006 Mar 01; 30(3):283-7. PubMed ID: 16448826
    [Abstract] [Full Text] [Related]

  • 23. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, Fillmore H.
    Neurosurgery; 1997 Oct 01; 41(4):908-15. PubMed ID: 9316053
    [Abstract] [Full Text] [Related]

  • 24. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
    Wang J, Liu X, Jiang W.
    Chin Med J (Engl); 2000 Oct 01; 113(10):957-60. PubMed ID: 11775848
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
    Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Krüger S, Sczakiel G, Jocham D.
    BJU Int; 2005 Feb 01; 95(3):416-20. PubMed ID: 15679806
    [Abstract] [Full Text] [Related]

  • 26. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S, Inui M, Kamei T, Nakase M, Okumura K, Tagawa T.
    Oncol Rep; 2006 Jun 15; 15(6):1563-8. PubMed ID: 16685396
    [Abstract] [Full Text] [Related]

  • 29. [Effect of phosphorothioate antisense Bcl-xL oligodeoxynucleotides on apoptosis and thermosensitivity of BcaCD885 cells].
    He YW, Bian L, Liang XH.
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Apr 15; 22(2):112-4. PubMed ID: 15190790
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 15; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 33. [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells].
    Lei XY, Zhang H, He DM.
    Ai Zheng; 2002 Dec 15; 21(12):1301-4. PubMed ID: 12520735
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
    Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A.
    Cancer Gene Ther; 1995 Sep 15; 2(3):207-12. PubMed ID: 8528964
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A.
    Urology; 1999 Dec 15; 54(6A Suppl):36-46. PubMed ID: 10606283
    [Abstract] [Full Text] [Related]

  • 40. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
    Yoo BH, Bochkareva E, Bochkarev A, Mou TC, Gray DM.
    Nucleic Acids Res; 2004 Dec 15; 32(6):2008-16. PubMed ID: 15064360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 666.